These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 23161334)

  • 41. A dose-escalation study of pemetrexed and docetaxel in non-small-cell lung cancer.
    Kotsakis A; Agelaki S; Vardakis N; Stathopoulos G; Vamvakas L; Kalykaki A; Kentepozidis N; Kontopodis E; Sfakiotaki G; Mavroudis D; Georgoulias V
    Cancer Chemother Pharmacol; 2011 Aug; 68(2):415-22. PubMed ID: 21069335
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A phase I trial of a Bcl-2 antisense (G3139) and weekly docetaxel in patients with advanced breast cancer and other solid tumors.
    Marshall J; Chen H; Yang D; Figueira M; Bouker KB; Ling Y; Lippman M; Frankel SR; Hayes DF
    Ann Oncol; 2004 Aug; 15(8):1274-83. PubMed ID: 15277270
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Phase I trial of weekly docetaxel, weekly doxorubicin, daily oral cyclophosphamide, and G-CSF (ConTAC regimen) in advanced malignancies.
    Wesolowski R; Peereboom D; Weiss P; Elson P; Thomas Budd G
    Invest New Drugs; 2010 Aug; 28(4):502-8. PubMed ID: 19434371
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A phase I study of docetaxel and bexarotene.
    Wildi JD; Baggstrom MQ; Suresh R; Read W; Fracasso PM; Govindan R
    Chemotherapy; 2008; 54(2):125-30. PubMed ID: 18332628
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Phase I clinical and pharmacokinetic study of ombrabulin (AVE8062) combined with cisplatin/docetaxel or carboplatin/paclitaxel in patients with advanced solid tumors.
    Bahleda R; Sessa C; Del Conte G; Gianni L; Capri G; Varga A; Oprea C; Daglish B; Hospitel M; Soria JC
    Invest New Drugs; 2014 Dec; 32(6):1188-96. PubMed ID: 24898305
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A dose escalation study of docetaxel plus capecitabine in combination with gemcitabine in patients with advanced solid tumors.
    Amarantidis K; Houhouli K; Papatheodorou K; Miloussis A; Matthaios D; Chatzaki E; Lyrantzopoulos N; Tsaroucha A; Tentes A; Kakolyris S
    Oncol Res; 2006; 16(6):281-7. PubMed ID: 17476973
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A phase Ib trial of continuous once-daily oral afatinib plus sirolimus in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer and/or disease progression following prior erlotinib or gefitinib.
    Moran T; Palmero R; Provencio M; Insa A; Majem M; Reguart N; Bosch-Barrera J; Isla D; Costa EC; Lee C; Puig M; Kraemer S; Schnell D; Rosell R
    Lung Cancer; 2017 Jun; 108():154-160. PubMed ID: 28625629
    [TBL] [Abstract][Full Text] [Related]  

  • 48. An European Organisation for Research and Treatment of Cancer phase I study of lapatinib and docetaxel as neoadjuvant treatment for human epidermal growth factor receptor 2 (HER2) positive locally-advanced/inflammatory or large operable breast cancer.
    Bonnefoi H; Zaman K; Debled M; Fiche M; Fournier M; Nobahar M; Pierga JY; Koch KM; Bartlett J; Zimmer A; Marreaud S; Bogaerts J; Cameron D
    Eur J Cancer; 2013 Jan; 49(2):281-9. PubMed ID: 22999386
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Phase I study of afatinib combined with nintedanib in patients with advanced solid tumours.
    Bahleda R; Hollebecque A; Varga A; Gazzah A; Massard C; Deutsch E; Amellal N; Farace F; Ould-Kaci M; Roux F; Marzin K; Soria JC
    Br J Cancer; 2015 Nov; 113(10):1413-20. PubMed ID: 26512876
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Bi-weekly docetaxel in the adjuvant treatment of node-positive or high-risk breast cancer patients: phase I study of the Shiga Breast Cancer Study Group.
    Abe H; Ogawa H; Okino T; Kato M; Sako H; Sano H; Shimomatsuya T; Suwa H; Higashide S
    Breast Cancer; 2009; 16(1):37-41. PubMed ID: 18493840
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Phase I and pharmacokinetic study of docetaxel in combination with epirubicin and cyclophosphamide in advanced cancer: dose escalation possible with granulocyte colony-stimulating factor, but not with prophylactic antibiotics.
    Rischin D; Ackland SP; Smith J; Garg MB; Clarke S; Millward MJ; Toner GC; Zalcberg J
    Ann Oncol; 2002 Nov; 13(11):1810-8. PubMed ID: 12419756
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Docetaxel-ifosfamide combination in patients with advanced breast cancer failing prior anthracycline-based regimens: results of a phase I-II study.
    Kosmas C; Tsavaris N; Mylonakis N; Tsakonas G; Gassiamis A; Skopelitis H; Polyzos A; Malamos N; Karabelis A
    J Chemother; 2007 Jun; 19(3):322-31. PubMed ID: 17594929
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Phase I and pharmacokinetic study of pazopanib and lapatinib combination therapy in patients with advanced solid tumors.
    de Jonge MJ; Hamberg P; Verweij J; Savage S; Suttle AB; Hodge J; Arumugham T; Pandite LN; Hurwitz HI
    Invest New Drugs; 2013 Jun; 31(3):751-9. PubMed ID: 23054212
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Phase I safety and pharmacokinetic study of SU-014813 in combination with docetaxel in patients with advanced solid tumours.
    de Jonge MJ; Dumez H; Kitzen JJ; Beuselinck B; Verweij J; Courtney R; Battista A; Brega N; Schöffski P
    Eur J Cancer; 2011 Jun; 47(9):1328-35. PubMed ID: 21439816
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Phase I study of the safety and pharmacokinetics of trabectedin with docetaxel in patients with advanced malignancies.
    von Mehren M; Bookman M; Meropol NJ; Weiner LM; Sherman E; Li J; Knoblauch R; Parekh T; Cohen RB
    Cancer Chemother Pharmacol; 2015 May; 75(5):1047-55. PubMed ID: 25791363
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Phase I Study of Docetaxel and Temsirolimus in Refractory Solid Tumors.
    Amin M; Gao F; Terrero G; Picus J; Wang-Gillam A; Suresh R; Ma C; Tan B; Baggstrom M; Naughton MJ; Trull L; Belanger S; Fracasso PM; Lockhart AC
    Am J Clin Oncol; 2021 Sep; 44(9):443-448. PubMed ID: 34310349
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A phase I and pharmacokinetic study of docetaxel administered in combination with continuous intravenous infusion of 5-fluorouracil in patients with advanced solid tumors.
    Van Den Neste E; de Valeriola D; Kerger J; Bleiberg H; Kusenda Z; Brassinne C; Bartholomeus S; Selleslags J; Hennebert P; Wythouck H; Cazenave I; Lefresne-Soulas F; Piccart M
    Clin Cancer Res; 2000 Jan; 6(1):64-71. PubMed ID: 10656433
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A phase I dose-escalation trial of 2-deoxy-D-glucose alone or combined with docetaxel in patients with advanced solid tumors.
    Raez LE; Papadopoulos K; Ricart AD; Chiorean EG; Dipaola RS; Stein MN; Rocha Lima CM; Schlesselman JJ; Tolba K; Langmuir VK; Kroll S; Jung DT; Kurtoglu M; Rosenblatt J; Lampidis TJ
    Cancer Chemother Pharmacol; 2013 Feb; 71(2):523-30. PubMed ID: 23228990
    [TBL] [Abstract][Full Text] [Related]  

  • 59. PR-104 a bioreductive pre-prodrug combined with gemcitabine or docetaxel in a phase Ib study of patients with advanced solid tumours.
    McKeage MJ; Jameson MB; Ramanathan RK; Rajendran J; Gu Y; Wilson WR; Melink TJ; Tchekmedyian NS
    BMC Cancer; 2012 Oct; 12():496. PubMed ID: 23098625
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Phase I study of combination therapy with S-1 and docetaxel (TXT) for advanced or recurrent gastric cancer.
    Yoshida K; Hirabayashi N; Takiyama W; Ninomiya M; Takakura N; Sakamoto J; Nishiyama M; Toge T
    Anticancer Res; 2004; 24(3b):1843-51. PubMed ID: 15274365
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.